BioRestorative Therapies has the GF Score of 51, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes BioRestorative Therapies
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
BioRestorative Therapies GF Score Related Terms
FRA:9OF vs CVKD, JSPR, APRE: GF Score Comparison
For the Biotechnology subindustry, BioRestorative Therapies's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's GF Score distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's GF Score falls into.
BioRestorative Therapies (FRA:9OF) has a GF Score of 51 as of Jul. 02, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on BioRestorative Therapies and its competitors. This is near median its historical median of 53.00. Over the past decade, BioRestorative Therapies' GF Score has ranged from 20.00 to 70.00.
Is BioRestorative Therapies' GF Score too high?
BioRestorative Therapies' current GF Score of 51 is near median its 10-year median of 53.00. Over the past 10 years, this metric has ranged from a low of 20.00 to a high of 70.00. Overall, BioRestorative Therapies has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' GF Score compare to CVKD and JSPR?
BioRestorative Therapies' GF Score of 51 can be compared against companies in the Biotechnology industry. Historically, BioRestorative Therapies' own GF Score has ranged from 20.00 to 70.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on BioRestorative Therapies and its competitors. BioRestorative Therapies's current GF Score is 51, which is near median its own 10-year median of 53.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.26, compared to a current price of €0.32 — trading 74.4% below its estimated fair value. The current GF Score is 51, which is near median its 10-year median of 53.00. BioRestorative Therapies' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current GF Score is 51 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.32 is trading 74.4% below its estimated GF Value™ of €1.26.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for FRA:9OF:
GF Score: 51 (near median its 10-year median of 53.00)
GF Value™: €1.26 vs. price of €0.32 (74.4% below fair value)
No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
51GF Score
Get the complete analysis for FRA:9OF
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9OF has been successfully added to your 